Agilent Technologies Finalizes Acquisition of BIOVECTRA

Agilent Technologies has successfully finalized its acquisition of BIOVECTRA. This strategic move aims to enhance Agilent’s capabilities in the biopharmaceutical market. By integrating BIOVECTRA’s expertise in biologics and complex drug development, Agilent is poised to strengthen its position as a key player in the life sciences sector. The acquisition is expected to foster innovation and improve service offerings, benefiting customers worldwide.